Alkeus Pharmaceuticals, Inc.

Alkeus Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in Cambridge, Massachusetts. Founded in 2010, Alkeus is focused on developing therapies for serious eye diseases with high unmet need. Their lead candidate, gildeuretinol acetate (ALK-001), is a novel molecule designed to reduce the dimerization of vitamin A without disrupting vision. This compound is currently being evaluated in clinical trials for the treatment of Stargardt disease and geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Alkeus has demonstrated the potential of gildeuretinol in clinical trials. In a Phase 2 study for Stargardt disease, gildeuretinol showed a clinically significant slowing of the growth of retinal lesions. Additionally, the SAGA study in patients with GA secondary to AMD showed a clinically meaningful reduction in the GA lesion growth rate. The company is driven by a mission to positively impact the lives of people living with degenerative eye diseases and is actively working towards bringing oral gildeuretinol to those in need.

Alkeus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of retinal diseases, specifically Stargardt disease and Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). Their mission is to develop and deliver innovative therapies that address the underlying cause of these conditions, ultimately preserving and restoring sight for patients worldwide. This mission is driven by their belief that there is a critical unmet need for effective treatments for these diseases, and they are committed to advancing their lead candidate, gildeuretinol acetate (ALK-001), through clinical trials and regulatory approval to bring hope and relief to those affected by these debilitating disorders.

Alkeus Pharmaceuticals promotes a culture of innovation and collaboration focused on driving scientific advancements in the treatment of retinal disorders. The company emphasizes a patient-centric approach, with a strong commitment to developing breakthrough therapies that improve the lives of individuals affected by Stargardt disease and other degenerative eye conditions. This mission is driven by a dynamic team of dedicated professionals who work together to achieve ambitious goals and bring their innovative therapies to market.

Alkeus Pharmaceuticals is committed to building a diverse and inclusive workplace, valuing the unique perspectives and experiences of its employees. While their website doesn't explicitly state a diversity, equity, and inclusion policy, they are hiring for key roles across all functions, including medical affairs, regulatory, commercial, manufacturing, clinical, legal, financial, human resources, and business development. This suggests an effort to create a diverse and representative team. The company actively seeks to build a dynamic, patient-focused company, which may include incorporating diverse perspectives to best serve their patient population.